Genfit GNFT.PA

Genfit SA was founded in 1999 and is headquartered in France. The late stage biopharmaceutical company is focused on the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases and nuclear receptor-based drug discoveries.

Company products are meant for patients with considerable unmet medical needs, corresponding to a lack of approved treatments.Genfit SA’s most advanced drug candidate, Elafibranor, is a potential treatment for NASH, a liver disease affecting millions of people worldwide.

The company is also working on the development of a new, non-invasive and easy-to-access blood-based in vitro diagnostic test to identify patients with NASH who may be appropriate candidates for drug therapy. Genfit employs approximately 150 people and has a portfolio that includes 629 patent applications or patents granted in 50 countries.

During the first quarter of fiscal 2019, the company reported that following the capital increase and its listing on Nasdaq, cash and cash equivalents totaled €314.1 million. Track this instrument for more updates and news on the current GNFT.PA value.